SOX2 and cancer: For instance, several stemness markers, such as OCT4, C-MYC, KLF4, NANOG, SALL4, and SOX2 are reported to be highly expressed in various cancers and associated with poor clinical outcomes of patients [12,13,14,15,16,17,18,19,20,21,22].